GlobeNewswire

GridGain® Experts Share Hands-On Advice About How In-Memory Computing Can Make New or Existing Applications 1,000x Faster and Scalable to Petabytes

Dela

FOSTER CITY, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite(TM), today highlighted its ongoing commitment to helping businesses of all sizes understand how in-memory computing can help them address the speed and scalability requirements of modern, data-intensive applications.

"The demand for information about in-memory computing continues to soar as more enterprises recognize their need for real-time performance as they create or scale out applications related to digital transformation, omnichannel marketing and regulatory compliance initiatives," said Terry Erisman, Vice President of Marketing at GridGain. "Our in-memory computing experts enjoy sharing their practical knowledge about how to apply distributed in-memory computing technology to a range of data-intensive use cases."

To start the year, GridGain Founder and CTO Nikita Ivanov spoke at Persistent Memory Summit 2018, where he served as a panelist on "Hype to Reality, a Panel Discussion with Leaders of Real World Persistent Memory Applications."

Over the coming months, GridGain will host or participate in the following conferences, webinars and meetups:

Webinars

Workshops

  • Workshop: In-Memory Computing Essentials for Data Scientists, February 15, 2018 - In this hands-on workshop by GridGain Technology Evangelist Akmal Chaudhri, attendees will be introduced to the fundamental capabilities of in-memory computing platforms that boost highly-loaded applications, research projects, risk analysis and fraud detection tasks by storing and processing massive amounts of data in memory and on disk across a cluster of machines.
  • Amsterdam Java User Group, March 8, 2018 - GridGain Technology Evangelist Akmal Chaudhri will lead a workshop titled "In-Memory Computing Essentials for Java Developers."

Conferences

  • DeveloperWeek 2018 - February 3-7, 2018 - On Wednesday, February 7, GridGain Product Manager and Apache Ignite PMC Chairman Denis Magda will present "Apache Ignite Service Grid: Foundation of Your Microservices-Based Solution." 

Meetups

  • In-Memory in Manhattan! January 25, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Building Consistent and Highly Available Distributed Systems with Apache Ignite and GridGain."
  • Los Angeles Kubernetes Meetup, January 31, 2018 - GridGain Solution Architect Dani Traphagen will present "Deploy like a Boss: Using Kubernetes and Apache Ignite!"
  • Big Data Application Meetup, January 31, 2018 - GridGain Product Manager and Apache Ignite PMC Chairman Denis Magda will present "Apache Spark and Apache Ignite: Where Fast Data Meets the IoT." 
  • The New York City Java Meetup Group, January 31, 2018 - GridGain Senior Solutions Architect Fotios Filacouris will present "Java and In-Memory Computing: Apache Ignite."
  • London In-Memory Computing Meetup, February 7, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Building Consistent and Highly Available Distributed Systems with Apache Ignite and GridGain."
  • The Boston MySQL Meetup Group, February 12, 2018 - GridGain Senior Solutions Architect Fotios Filacouris will present "Turbocharge your MySQL Queries In-Memory with Apache Ignite." 
  • The Boston Java Meetup Group, February 13, 2018 - GridGain Senior Solutions Architect Fotios Filacouris will present "Java and In-Memory Computing: Apache Ignite."
  • Symbion IoT Meetup, February 14, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Apache Ignite: The In-Memory Hammer in Your Data Science Toolkit." 
  • Sydney Cassandra Users, February 13, 2018 - Rachel Pedreschi, GridGain's Principal Solutions Architect, will present "Ignite your Cassandra Love Story: Caching Cassandra with Apache Ignite."
  • San Francisco Kubernetes Meetup , February 15, 2010 - GridGain Product Manager and Apache Ignite PMC Chairman Denis Magda will present "Distributed Database DevOps Dilemmas? Kubernetes to the Rescue!"
  • Berlin Kubernetes Meetup, February 21, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Distributed Database DevOps Dilemmas? Kubernetes to the Rescue!"
  • Big Data, Berlin, February 22, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Apache Ignite: The In-Memory Hammer in Your Data Science Toolkit."
  • Amsterdam Java User Group, March 7, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Catch An Intro to the Java-Powered Apache Ignite - Memory-Centric Distributed Platform."

             
About GridGain® Systems
GridGain Systems is revolutionizing real-time data access and processing by offering enterprise-grade in-memory computing solutions built on Apache® Ignite(TM). GridGain solutions are used by global enterprises in financial, software, ecommerce, retail, online business services, healthcare, telecom and other major sectors. GridGain solutions connect data stores (SQL, NoSQL, and Apache® Hadoop®) with cloud-scale applications and enable massive data throughput and ultra-low latencies across a scalable, distributed cluster of commodity servers. GridGain is the most comprehensive, enterprise-grade in-memory computing platform for high volume ACID transactions, real-time analytics, and hybrid transactional/analytical processing. For more information, visit gridgain.com.

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache,  Apache CassandraCassandra, Apache Hadoop, Hadoop, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GridGain Systems via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum